Principal Investigators: Bruce N. Cronstein, MD
Regenosine is developing and commercializing first-in-class musculoskeletal regenerative therapies. Its proprietary platform technology harnesses the healing potential of the purinergic system which plays a critical role in maintaining musculoskeletal tissue homeostasis. The lead product is a proprietary formulation for regenerating cartilage in joints with established osteoarthritis, targeting a rapidly growing joint preservation market. The goal is to offer a disease modifying therapy with uncompromising efficacy relative to existing technologies. By developing this disease modifying therapy, Regenosine will significantly improve clinical outcomes and patient quality of life and reduce the total healthcare delivery costs associated with osteoarthritis.